Tanaka Kenichi A, Levy Jerrold H
Department of Anesthesiology, Division of Cardiothoracic Anesthesia, Emory Healthcare, 1364 Clifton Road N.E., Atlanta, GA 30322, USA.
Hematol Oncol Clin North Am. 2007 Feb;21(1):33-50. doi: 10.1016/j.hoc.2006.11.008.
Thrombin is an essential serine protease for survival. Since the discovery of heparin in the early twentieth century, significant advances have been made in the understanding of thrombin structure and function in coagulation system. Endogenous anticoagulant proteins in blood tightly regulate thrombin generation, but additional anticoagulant agents may be necessary to suppress excessive thrombin formation or defective anticoagulant proteins. Despite the availability of an array of anticoagulant agents based on chemical and biological engineering technologies, anticoagulation therapy remains a challenge for clinicians in terms of balancing bleeding and thrombosis. The aim of this article is to review endogenous serine protease inhibitors and novel antithrombotic agents in relation to pharmacologic regulation of thrombin.
凝血酶是生存所必需的丝氨酸蛋白酶。自20世纪初发现肝素以来,在理解凝血系统中凝血酶的结构和功能方面取得了重大进展。血液中的内源性抗凝蛋白严格调节凝血酶的生成,但可能需要额外的抗凝剂来抑制过量的凝血酶形成或有缺陷的抗凝蛋白。尽管有一系列基于化学和生物工程技术的抗凝剂,但在平衡出血和血栓形成方面,抗凝治疗对临床医生来说仍然是一项挑战。本文的目的是综述与凝血酶药理调节相关的内源性丝氨酸蛋白酶抑制剂和新型抗血栓药物。